Analysts foresee less revenue Gilead Sciences

Tomorrow the American Gilead Sciences will report its past quarter's results. For this year Gilead Sciences 's revenue will be around 21,29 billion USD. This is according to the average of the analysts' estimates. This is rather significant lower than 2016's revenue of 26,11 billion USD.

Historical revenues and results Gilead Sciences plus estimates 2018

The analysts expect for 2018 a net profit of 8,39 billion USD. According to most of the analysts the company will have a profit per share for this book year of 6,47 USD. So the price/earnings-ratio equals 11,42.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a limited 1 percent.

Recent target prices around 89 USD

Leerink Swann & Company, Berenberg and Jefferies & Co. recently provided recommendations for the stock.

Based on the current number of outstanding shares Gilead Sciences 's market capitalization 96,54 billion USD.

On Thursday the stock closed at 73,86 USD.

Historical stock prices Gilead Sciences from 2007 till 2018

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.